Geron Corporation (LON:0IV3)
1.600
-0.038 (-2.32%)
Feb 12, 2026, 5:03 PM GMT
Geron Company Description
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia.
The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation
| Country | United States |
| Founded | 1990 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 229 |
| CEO | Harout Semerjian |
Contact Details
Address: 919 East Hillsdale Boulevard Foster City, California 94404 United States | |
| Phone | 650 473 7700 |
| Website | geron.com |
Stock Details
| Ticker Symbol | 0IV3 |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US3741631036 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Harout Semerjian | Chief Executive Officer, President and Director |
| Michelle J. Robertson | Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial and Accounting Officer |
| Dr. Joseph Emile Eid M.D. | Executive Vice President of Research and Development and Chief Medical Officer |
| Shanthakumar Tyavanagimatt | Senior Vice President and Chief Technical Officer |
| Dawn Schottlandt CFA | Senior Vice President of Investor Relations and Corporate Affairs |
| Aron Feingold | Vice President of Investor Relations and Corporate Communications |
| Shannon T. Odam | Executive Vice President and Chief People Officer |
| Bryan Ridgell | Senior Vice President of Portfolio and Project Management and Chief of Staff |
| Ahmed ElNawawi | Executive Vice President and Chief Commercial Officer |